Celltrion’s Truxima launched in Europe

April 27, 2017 1:04 PM

Last week, Celltrion stated that, official sales of its second biosimilar, Truxima, which was approved by the European Medicines Agency (EMA) has started in England.

Truxima is a biosimilar monoclonal antibody used in treatments of Non-Hodgkin lymphoma which is a kind of hematological cancers and rheumatoid arthritis.

Celltrion received approval for Truxima sales by the Ministry of Food and Drug Safety in Korea last November, and also by European Medicines Agency (EMA) in February this year.

Since last April, Celltrion has provided Truxima to about 50 hospitals in England with its affiliate, Celltrion Healthcare, which is in charge of overseas marketing for the company products, and with Napp Pharmaceuticals Ltd, the distribution partner in England; also, at each hospital, hundreds of blood cancer and rheumatoid arthritis patients were confirmed to have completed their first Truxima™ administration. Among these patients, they included the patients switched to Truxima from originator infliximab.

A Celltrion official said “Despite it’s early stage of launching, positive market sentiment for Truxima has been detected in Europe. With the advent of the first biosimilar of anticancer in Europe, patients all around the world, medical care and pharmaceutical makers are paying keen attention to the market reaction.” The company plans to increase the market share to block the entry of competitors, while increasing the confidence of the medical community based on accumulated prescription data.” The expert also added, “We will try to obtain licenses and sales for Truxima in the United States and other countries as soon as possible so that patients around the world can benefit from the biosimilar.”


Source: Celltrion press release

Leave a Reply

Twitter ID
(ID only. No links or "@" symbols)

Latest News on Biosimilar News

Share an Article?

Writing an article is not only a great way to share your knowledge, but it is also a great way to give back to the community.

We value all our contributors and if you have a website, we will surely give a link back to your site and products.
Wanna contribute?


Biosimilar News was started for the people who are interested in this rapidly growing business area. So if you have suggestions or feedback on how we can improve, please let us know. If you want to see a specific topic covered, answer to a specific question, or anything else of this sort, just write us. We do our best to keep up!
Make a suggestion now!